OpenEvidence

AI copilot for doctors that synthesizes peer-reviewed medical evidence at the point of care

Healthcare 📍 Miami, FL Founded 2021

Current Valuation

$12B

as of 2026-Q1

DECACORN

OpenEvidence is a Miami-based clinical AI company often called the 'ChatGPT for doctors' — its copilot synthesizes peer-reviewed medical literature into instantaneous, citation-backed answers at the point of care. Founded in 2021 by Kensho founder Daniel Nadler, it closed a $250M Series D in January 2026 co-led by Thrive Capital and DST Global at a $12B valuation, doubling from $6B six months earlier. Sacra estimates 2025 revenue at $150M, up over 1,800% YoY, with widespread adoption among U.S. physicians.

Company Profile

CEO

Daniel Nadler

Founded

2021

Miami, FL

Employees

~80

Total Raised

$700M

Est. Revenue

$150M (2025)

Growth

+1,803% YoY revenue growth (Sacra)

Last Round

Series D — $250M (Jan 2026) · Lead: Thrive Capital / DST Global (co-led)

IPO Status

private

Founders & Key People

Daniel NadlerZachary Ziegler

Investors

Thrive Capital · DST Global · Sequoia Capital · Kleiner Perkins · Coatue · Google Ventures

Products

OpenEvidence Clinical AI Copilot
Point-of-Care Evidence Search
Specialty-Specific Knowledge Graphs
EHR-Integrated Decision Support

Competitors

UpToDate (Wolters Kluwer) · DynaMed · Hippocratic AI · Abridge · Glass Health

AIHealthcareClinical Decision SupportDecacornMedical AI